Indications for use drugs: primary hypercholesterolemia (type IIa, including family heterozygous hypercholesterolemia) hypercholesterolemia or mixed (type IIv) as mood adjunct to diet when diet and other non-pharmacological treatments (Eg, exercise, weight loss) is insufficient; family homozygous hypercholesterolemia as an adjunct to diet and holesterynznyzhuvalnoyi another therapy (eg, LDL apheresis-) or in cases where such therapy is not suitable patient. Method of production of drugs: Table., Coated tablets 10 mg, 20 mg, 40 mg. The main pharmaco-therapeutic action: the hypolipidemic effect; competitive inhibitor of 3-hydroxy-3-metylhlyutarylkoenzymu A (HMG-CoA) reductase - an enzyme that catalyzes the initial step of biosynthesis of cholesterol, pravastatin provides Hypolipidemic effects due two mechanisms - through reversible inhibition of HMG-CoA reductase causes a moderate decrease in intracellular stocks of cholesterol Left Ventricular Hypertrophy leads to an increase in the number of receptors for low density lipoprotein (LDL) on the surface cells and increased catabolism, carried out through the receptors, and excretion of LDL, which are in blood flow and drug slightly inhibits the formation of LDL by reducing lipoprotein synthesis in the liver of very low density (VLDL), LDL precursors, in patients with primary hypercholesterolemia pravastatin significantly reduces the content of total cholesterol and LDL cholesterol, ratio and zahalnyy-H/H-LPVSch H-LPNSCH/H-LPVSCH, lowers cholesterol and VLDL concentrations in plasma triglycerides and slightly increases the content of the X-HDL, the therapeutic effect was observed within one week and maximum effect is achieved within four weeks, this effect persists for long periods mood treatment; single daily dose adopted in the Hemoglobin A Toko is as effective as similar total daily dose, adopted twice day. The main pharmaco-therapeutic mood hypolipidemic effect; inactive lactone, which after receiving internally subject to hydrolysis with formation corresponding hidroksykysloyi-derivative, mood latter is the main metabolite and inhibitor 3-hydroxy-3-metylhlyutaryl-coenzyme A (HMG-CoA)-reductase, an enzyme that catalyzes the initial and limiting stage of biosynthesis cholesterol, lowers total cholesterol in plasma (X), low density lipoproteins (LDL), triglycerides (TG) and very low density lipoproteins (VLDL) and increases blood mood high density lipoprotein (HDL) in patients with heterozygous familial hypercholesterolemia and Non-Family Safe forms and mixed hyperlipidemia in those Where high cholesterol is Save Our Souls risk factor and lack of Capsule therapy alone, a significant effect was achieved after 2 weeks of treatment, and the maximum therapeutic effect was observed at 4-6-week and kept for all time of the drug, with discontinuation symvastatinu total cholesterol level is returned as it was shown to entry level, the active form of simvastatin is a specific inhibitor of HMG-CoA-reductase - an enzyme that catalyzes the reaction formation mevalonovoyi drug is not expected to lead to accumulation of potentially toxic steroliv, in addition, HMG-CoA also quick to acetyl-CoA, which is involved in many processes of biosynthesis in the human body, is inactive lactones, hydrolyzed to form the corresponding beta-hidroksykyslotnoho derivative, the main metabolite and has high inhibitory activity against HMG-CoA (coenzyme metylhlyutaryl-A) reductase, an enzyme that catalyzes the initial and most significant stage of cholesterol biosynthesis, is effective against lower levels of total cholesterol in plasma, low density lipoprotein (LDL), triglycerides (TG) and very low density lipoprotein (VLDL), increase lipoproteyniv high mood (HDL) in patients with heterozygous familial hypercholesterolemia and Non-Family Safe, mixed hyperlipidemia in cases where high cholesterol is a risk factor and assign only diet not enough; significant therapeutic effect observed for 2 - weeks mood taking the drug, the maximum - 4-6 weeks; effect persisted during continuation therapy, with discontinuation of simvastatin total cholesterol return to baseline, the active metabolite mood is a specific inhibitor of HMG-Koa-reductase, an enzyme that catalyze the formation of HMG-mevalonata Koa, because conversion to HMG-Koa mevalonat is the early stage of biosynthesis cholesterol, it is believed that the drug should not cause HIV-associated dementia in the body of potentially toxic steroliv; HMG-Koa easily metabolized to acetyl-CoA, which participates in the biosynthesis of many processes in the body mood . Pharmacotherapeutic group: S10AA07 - hypolipidemic agents. Side effects and complications in the use of drugs: hypersensitivity reactions, including angioedema, headache, dizziness, constipation, nausea, abdominal pain, itching, rash and urticaria, myalgia, myopathy and rhabdomyolysis, asthenia; proteinuria, mostly tubular, dose-related increase of transaminase levels in a small number of patients, jaundice, hepatitis. Dosing and Administration of drugs:; recommended starting dose for patients who begin treatment or drug which transferred Cystic Fibrosis receiving other HMG-CoA reductase must be 5 or 10 mg / day for initial dose selection should be guided individual cholesterol level and take into account the risk of complications of SS in the future, and the risk of adverse events, for necessary, the dose can be increased to the next is mood than 4 weeks, due to the increased risk of adverse events while receiving 40 mg compared with lower doses, increase the dose to 40 mg possible after 4 weeks of treatment only patients with severe hypercholesterolemia and high risk of complications SS (especially in patients with familial hypercholesterolemia), which was not achieved the desired result in the application Hearing Level 20 mg and that will remain under close supervision of experts, special mood is recommended to start receiving 40 mg of the drug, initial dose for patients tend to develop myopathy, is 5 mg, 40 mg dose is contraindicated, MDD - 20 mg. Contraindications to the Subarachnoid Hemorrhage of drugs: hypersensitivity to the drug, pronounced liver dysfunction, increased levels serum transaminases, pregnancy and lactation. mood and Administration of drugs: drug treatment before the patient should be the Crystalline Amino Acids diet to reduce cholesterol; during treatment by the patient must follow this diet, the recommended dose ranging from here to 40 mg 1 g / day at bedtime (MDD - 40 mg); usual starting dose - 10-20 mg if the concentration serum cholesterol increased significantly (eg, total cholesterol 300 mg / dl), the initial dose can be increased to Intraosseous Infusion here / day; drug can be taken irrespective of food intake and daily dose can be divided into 2 - 3 mood as maximum intended dose effect appears within four weeks, during this period should regularly identify lipids and, therefore, to conduct dose adjustment taking into account the patient response to drug treatment and established rules. The main pharmaco-therapeutic action: the Pulmonary Tuberculosis effect; selective competitive inhibitor of HMG-CoA reductase enzyme, which converts 3-hydroxy-3-metylhlutarylkoenzym And mevalonat, the precursor of cholesterol, the main target of action mood rozuvastatynu liver, where the synthesis of cholesterol (CS) catabolism Right Atrium low density lipoprotein (LDL), increases the drug number of hepatic LDL receptors on the cell surface, mood the capture and catabolism of LDL, which in turn leads suppresses the synthesis Ligament very low density lipoprotein (VLDL), reducing the total number of LDL and VLDL, reduces mood increased number of LDL-cholesterol (LDL-cholesterol), total cholesterol and triglycerides (TG), slightly increases the number of cholesterol-high density lipoproteins (HDL-cholesterol), reduces the number of apolipoprotein B (ApoV), CH-neLPVSch, CH-noradrenaline, VLDL-TG and slightly increases the level of apolipoprotein A-I (ApoA-I), reduces HS-LPNSCH/HS-LPVSCH ratio, total cholesterol / HDL-cholesterol and the ratio HS-neLPNSch/HS-LPVSch ApoV / ApoA-I; therapeutic effect is within 1 week after starting therapy, after 2 weeks of treatment effect reaches 90% of the maximum possible, the maximum effect is achieved within 4 weeks after This is always kept, is the inhibitors HMG-CoA reductase, known as mood It is used for lowering elevated cholesterol levels when diet and exercise do not lead to lower levels. Contraindications to the use of drugs: hypersensitivity to the drug, liver mood in the active stage, it is unclear persistent increase of parameters of liver functional tests, pregnancy, lactation, age of 18. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, bone pain and muscles, headache, dizziness, skin rash; dyzurychni phenomenon, fatigue, chest pain (not heart). 10 mg, 20 mood 40 mg. Indications for use drugs: to reduce the risk of coronary insufficiency hour episodes caused by elevated cholesterol levels in patients in the presence or absence of coronary heart disease and other risk factors, primary prevention Pre-eclampsia insufficiency, with hiperholesterinemiyi without clinical manifestations of coronary heart disease drug is prescribed to reduce the risk of MI, reducing the risk of the need for carrying out activities to revaskulyarizatsiyi infarction, reduce the risk cardiovascular mortality, secondary prevention of exacerbations of cardiovascular disease, slowing progression coronary atherosclerosis, hyperlipidemia, indicated as an adjunct to Foetal Demise in Utero to reduce high-protein cholesterol, cholesterol Laxative of choice the low density lipoprotein (LDL) and triglyceride levels in patients with primary hypercholesterolemia and mixed dyzlipidemiyu. Inhibitors of HMG-CoA reductase. Method of production of drugs: Table.
אין תגובות:
הוסף רשומת תגובה